Join Evelyn Pyper, MPH, as she discusses how PicnicHealth is using real-world data to transform neurodegeneration research.
Evelyn Pyper, MPH discusses how a patient-centered approach to real-world data collection and evidence generation can transform research in neurodegeneration. Neurodegenerative diseases often affect both motor and cognitive function, produce emotional and social changes, and require significant caregiver support, all while stretching across a fragmented healthcare ecosystem. Participatory research that directly obtains patient consent, empowers patients, and simplifies the task of linking multiple data sources, can lead to a more comprehensive capture of medical histories. This presentation briefly explores ways in which patient-centered research can improve understanding of disease diagnoses, symptomatology, and progression.
Key Topics Include:
- The value of patient consent and patient-generated data in neurodegenerative disease research
- The importance of using unstructured data to construct a complete picture of patient health
- Real-world examples of how patient-centered data can improve our understanding of patient subpopulations
Click to watch the webinar recording. To view the presentation full screen simply click the square icon located in the bottom-right corner of the video-viewer.
Resources
To retrieve a PDF copy of the presentation, click on the link below the slide player. From this page, click on the “Download” link to retrieve the file.
Presenters
Senior Evidence Strategy Manager
Life Sciences Partnerships
PicnicHealth
Evelyn Pyper is Senior Evidence Strategy Manager at PicnicHealth, a patient-centric real-world data company. Her career in RWE spans the public and private sector, and regional and global markets - most recently as Assoc. Director, Market Access at J&J GPH. Evelyn is completing her DPhil in Evidence-Based Health Care at the University of Oxford.
Production Partner
PicnicHealth
PicnicHealth is giving patients unprecedented access to and control of their medical records, and with their consent, the opportunity to participate in research. Using industry leading machine learning, we deliver patient-level real-world data at scale to life sciences companies, unlocking the most complete view of real-world patient journeys.
Additional Content From Scientist.com
Circulating Nucleosome Quantification (Nu.Q®) Technology for Monitoring Target Engagement and Adverse Events in Oncology Trials
Join us for a comprehensive webinar featuring experts in epigenetics and assay development, focusing on the scientific foundations and applications of Nucleosome Quantification (Nu.Q®) Technology in the realms of drug development and disease monitoring.
Innovative Approaches to Assessing Thyroid Disruption: The 3D Human Thyroid Microtissue Model
Dr. Chad Deisenroth, PhD, from the US EPA, introduces an advanced human in vitro 3D thyroid microtissue model designed to evaluate thyroid hormone disruption, addressing current challenges with existing models.
Discover the Freshness of Frozen PBMCs – An Assessment of Cryopreservation Impact on T Cell Activation and Phenotype
Discover the impact of cryopreservation of PBMCs on T cell activation and phenotype in Lonza’s free webinar.
Additional Content From HealthEconomics.Com
Partnering with Disease Registries: The Value and Impact for Real-World Evidence Generation
In this webinar, Evidera experts present guidance on why strong connections with registry groups and stakeholder populations are important for generating relevant real-world evidence to advance treatments.
Minimizing the Impact of Cross-Cultural Differences in COA Translations
ICON's COA Linguistic Validation Leaders highlight the importance of Linguistic Validation and how equivalence should be a key focus during the development of Clinical Outcome Assessment translations.
Improving Patient Outcomes: AI-Based Phenotyping for Diagnosis, Treatment, and Clinical Trials
Watch a panel of OM1’s clinical experts in cardiometabolic disease, immunology, and mental health as they explore how Artificial Intelligence (AI) can find phenotypic patterns and unlock insights hidden in real-world data.
Related Content
Unraveling European Animal Welfare Legislation for Biotech & Pharma
This event illuminates the intricacies of animal welfare legislation, specifically comparing and distinguishing differences between EU, UK, and North American standards.
Understanding Animal Welfare Best Practices in Asia Pacific for Biotech & Pharma
In this event, we focus on the Asia Pacific region, uncovering the landscape of animal welfare legislation and its implications for pharmaceutical and biotech players.
Navigating Animal Welfare Legislation in North America: Insights for Biotech & Pharma
Watch as we delve into the nuances of animal welfare legislation in North America, specifically addressing the needs of clients and suppliers in the pharmaceutical and biotech sectors.